title: Radiotherapy confined to the tumor bed following breast conserving surgery current status, controversies, and future projects.
abstract: BACKGROUND
  The standard technique of radiotherapy (RT) after breast conserving surgery (BCS) is to treat the entire breast up to a total dose of 45-50 Gy with or without tumor bed boost. The majority of local recurrences occur in close proximity to the tumor bed. Thus, the necessity of whole breast radiotherapy has been questioned, and several centers have evaluated the feasibility and efficacy of sole tumor bed irradiation. The aim of this study was to review the current status, controversies, and future prospects of tumor bed irradiation alone after breast conserving surgery.
  
  
  METHODS
  Published prospective trials evaluating the feasibility and efficacy of radiotherapy confined to the tumor bed following breast conserving surgery were reviewed in order to analyze treatment results.
  
  
  RESULTS
  In three earlier studies, using tumor bed radiotherapy for unselected patients, the incidence of intra-breast relapse was reported in the range of 15.6-37%. However, in nine prospective phase I-II trials, sole brachytherapy (BT) with different dose rates, strict patient selection, and meticulous quality assurance, resulted in 95.6-100% local control rates. To date, only one phase III protocol has been initiated comparing the efficacy of tumor bed brachytherapy alone with conventional whole breast radiotherapy. The ideal extend of the planning target volume (PTV) for tumor bed radiotherapy alone has not been established yet. In most series, PTV was defined as the excision cavity with generous (1-3 cm) safety margins. Minimal requirement for PTV localization is the use of titanium clips to mark the walls of the excision cavity intraoperatively, but the combination of clip demarcation and three-dimensional (3-D) visual information obtained from cross-sectional images seems to be the best method to determine the target volume. 3-D virtual brachytherapy is also a promising method to minimize the chance of geographic miss. Recently developed techniques, such as intraoperative radiotherapy (IORT), as well as accelerated 3-D conformal external beam radiation therapy (3-D-CRT) were also found to be feasible for tumor bed radiotherapy alone.
  
  
  CONCLUSIONS
  In spite of the existing arguments against limiting radiotherapy to the tumor bed after breast conserving surgery, results of phase I-II studies suggest that tumor bed radiotherapy alone might be an appropriate treatment option for selected breast cancer patients. Whole breast radiotherapy remains the standard radiation modality used in the treatment of breast cancer, and brachytherapy as the sole modality should be considered as investigational. Further phase-III trials are suggested to determine the equivalence of sole tumor bed radiotherapy, compared with whole breast radiotherapy. Preliminary results with recently developed techniques (CT-image based conformal brachytherapy, 3-D virtual brachytherapy, IORT, 3-D-CRT) are promising. However, more experience is required to define whether these methods might improve outcome for patients treated with tumor bed radiotherapy alone.
authors.affiliation: National Institute of Oncology, Department of Radiotherapy, Budapest, Hungary. polgar@oncol.hu
authors.forename: Csaba
authors.initials: C
authors.lastname: Polgár
authors.forename: János
authors.initials: J
authors.lastname: Fodor
authors.forename: Tibor
authors.initials: T
authors.lastname: Major
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Takácsi-Nagy
authors.forename: Miklós
authors.initials: M
authors.lastname: Kásler
authors.forename: Josef
authors.initials: J
authors.lastname: Hammer
authors.forename: Erik
authors.initials: E
authors.lastname: Van Limbergen
authors.forename: György
authors.initials: G
authors.lastname: Németh
mesh_terms: D001918:Brachytherapy / Q000639:trends; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005544:Forecasting; D005858:Germany; D006801:Humans; D015412:Mastectomy, Segmental; D018365:Neoplasm, Residual / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011880:Radiotherapy Planning, Computer-Assisted / Q000639:trends; D018714:Radiotherapy, Adjuvant / Q000639:trends; D020266:Radiotherapy, Conformal / Q000639:trends